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Abstract. The role of CNS neuromodulators in cognitive neurorehabilitation can be related to two main issues: 1) the negative
impact on cognition of drug categories prescribed for different neurologic symptoms, such as spasticity, extrapyramidal symptoms,
or epileptic seizures; 2) their possible role in neuroprotection and amelioration of the cognitive status of the patient, especially
attention and memory. This paper reviews different pharmacological aspects of cognitive neurorehabilitation in epilepsy.
When approaching the role of central nervous system
(CNS) drugs in cognitive neurorehabilitation, one must
consider two main aspects: 1) the negative impact on
cognition of different drug categories; 2) the pharmaco-
logical instruments available for amelioration of cogni-
tive deficits. In this paper, as we consider epilepsy and
its management, we first make some relevant comments
on neurotransmitter relationships to cognition.
1. Neurotransmitters and cognition
From a psychopharmacological point of view, two
cognitive domains seem of most importance,namely at-
tention and memory. Current evidence suggests that the
former is interlinked with the dopamine/norepinephrine
systems, while the latter is dependent on the cholinergic
system [41]. In clinical practice, the most commonly
used agents to enhance attention are methylphenidate
and d-amphetamine. Pemoline and metamphetamine
are also available in some countries, but are not
as widely used, because of their liver toxicity and
abuse potential respectively. Both methylphenidate and
d-amphetamine mainly determine release of dopamine
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from presynaptic terminals, but they also inhibit the
dopamine transporter, and in some models they actually
reverse its direction, leading to further dopamine
release from the synapse. Methylphenidate is less
potent as a dopamine releaser, but is longer acting
than d-amphetamine. Another form of amphetamine,
l-amphetamine, releases norepinephrine as well as
dopamine through a similar mechanism and, in clini-
cal practice, a mixture of d,l-amphetamine is usually
prescribed.
Memory is one of the most complex functions of
the human brain and involves many neurotransmitters
and cortical-subcortical neuronal networks. However,
we know that specific disorders of the cholinergic
system are characterized by memory disturbances and
the therapeutic agents currently available, that can
improve memory function, usually act on this system
in some way or other. The major cholinergic strategies
for enhancing memory are cholinesterase inhibition
by a number of agents that are clinically available,
including donepezil, tacrine, rivastigmine, metrifonate,
physostigmine and galantamine. They represent an
important class of drugs now used widely in patients
with Alzheimer disease and other dementias, but they
may also find use in other neurological settings.
We now look at investigations in patients with
epilepsy based upon these theoretical foundations.
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2. Epilepsy, cognition and antiepileptic drugs
There is a considerable literature which suggests that
certain antiepileptic drugs and in particular polytherapy
markedly affect cognitive function in epilepsy. This
conclusion emerged from earlier studies which revealed
that many patients with epilepsy were treated with two
or more, often sedative, drugs and that tailoring ther-
apy from polytherapy to monotherapy had a beneficial
effect on cognition [48]. The data that has accumulated
over time, although it has generated some controversy,
suggest that the older, barbiturate-related compounds,
such as phenobarbital and phenytoin were more impli-
cated in this process than drugs such as carbamazepine
and valproic acid [26]. Thus, one important strategy
for enhancing and maximising cognitive abilities in
patients with epilepsy is to avoid polytherapy as far
as possible, and to attempt monotherapy regimes with
non-barbiturate compounds.
Unfortunately, although the era for enthusiastic
monotherapy treatment lasted some 20 years, since
around 1990 some ten new antiepileptic drugs have
become marketed for the treatment of epilepsy, and
polytherapy has once again become the name of the
game, especially for those with difficult to control
seizures, who are likely to come from a population of
patients already intellectually compromised on account
of the neurological processes underlying their seizures.
Interestingly, these newer compounds seem to have less
impact on cognitive function than some of the standard
treatments, although they have been subject to fewer
and less rigorous investigations. Within the spectrum
of new antiepileptics, the exception may be topiramate,
which, in several studies, has been shown to be associ-
ated with cognitive impairments [31,47]. It is of further
interest that topiramate seems to be associated with a
rather specific localised disruption of cerebral function,
namely the induction of an aphasia-like syndrome
referred to often as word finding difficulties [32]. These
effects seem reversible on stopping the drug.
3. Pharmacotherapy of cognitive deficits in
epilepsy
People with refractory epilepsy frequently complain
of cognitive impairment, and within the broad subject
of the neuropsychology of epilepsy, memory deficits
represent the dominant complaint in clinical practice,
and have been the subject of most neuropsychological
investigations [42,46]. Interestingly, several studies
have mentioned discrepancies between subjective
memory complaints and the objective results of neu-
ropsychological testing [20]. For example, Thomp-
son [46] following a review of the topic, concluded
that many patients who have memory complaints often
perform within normal limits on standardized memory
tests. Therefore, spontaneous complaints of memory
difficulties may overestimate the incidence of actual
impairment from a neurobiological perspective but,
on the other hand, formal neuropsychological studies
may underestimate the problem, being non-ecological
in their design, usually not measuring performance in
everyday situations and thus the real impact on the
everyday life of the patients.
Although the immediate and prolonged effects of
seizures [10] have a serious impact on cognitive func-
tions, memory impairment is rarely seen as a direct
consequence of these factors. However, the role of
localized dysfunction, related to on-going epileptic
focal activity in specific areas of the brain, is probably
one of the key factors for memory impairment [28]. For
example, it has now been well demonstrated that even
focal interictal spikes as revealed on the EEG can be
associated with specific cognitive impairments, includ-
ing interference with memory [5]. More recent studies
suggest an association between the length of seizure
history in patients with temporal lobe epilepsy and
cognitive decline, although different domains of
cognition have not been well studied [23]. Nonetheless,
these data emphasize the importance of attempting to
get good control of seizures for the benefit of adequate
cognition, and changes in drug treatment or improve-
ments of seizure control may have some limited
influence on memory impairment. The importance
of controlling interictal spikes, especially in younger
patients with cognitive and behaviour problems
remains a matter of controversy.
It is clear, however, that we need methods to treat
memory impairments in epilepsy in clinical practice.
Potentially two methods are available: behavioral
methods (i.e. training memory and the use of memory
aids) [45] and a pharmacological approach. We now
review the pharmacological possibilities of treatment.
Most of this work relates to memory, but we also refer
to some work on attention.
The neuropharmacological approach to memory
deficits in epilepsy relates to the axiom that drug treat-
ment is not targeted on structural damage but may be
of value in functional impairment, perhaps hastening
neuronal recovery from the seizure, improving function
of surviving neuronal structures and preventing further
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Table 1
Classification of psychostimulants and cognitive en-
hancers discussed in the text
Non-specific CNS stimulators
Dexamphetamine
Methylphenidate
Modafinil
Replacement of depleted neurotransmitters
Choline
Cholinesterase inhibitors
Physostigmine
Rivastigmine
Donepezil
Galantamine
Putative memory modulators
Vasopressin
ACTH
Cerebral blood flow enhancers and nootropics
Piracetam
Oxiracetam
Sabeluzole
neuronal damage [3]. Theoretically, four main groups
of compounds are present in the pharmacological
armamentarium of the epileptologist to ameliorate
memory functions: non-specific CNS stimulators,
substitutes for depleted neurotransmitters, memory
modulators and drugs that enhance the cerebral blood
flow (Table 1).
4. Non-specific CNS stimulators
Non-specific central CNS stimulators, such as
amphetamines or caffeine, are found to have a
positive effect on cognitive functions, particularly in
the presence of attentional dysfunction, slowed cogni-
tion and sedation [38,40]. Some CNS stimulants, such
as methylphenidate, are considered potentially epilep-
togenic. However, several studies have demonstrated
that generally stimulants can be safely used in patients
with brain injury and epilepsy [58] or in epilepsy with
co-morbid Attention-Deficit Hyperactivity Disorder
(ADHD) [13]. Most positive results have been found
for mental speed, arousal activation and associated
short term effects, mostly using d-amphetamines [3].
However there are few systematised studies devoted
especially to epilepsy. An open-label, non-randomised,
3-month study showed that methylphenidate was safe
and effective for patients with epilepsy who suffered
sedation, leading to clinically significant improvements
in attention, concentration and memory [30].
Modafinil is a newly introduced stimulant that may
work by altering the hypothalamic hypocretin-orexin
system, and which has been approved for the treatment
of excessive daytime sleepiness in narcolepsy. Several
studies reported favourable results on attention and
memory in patients with brain injury, multiple sclerosis
and ADHD [12,43,44,55], but to date we know of no
studies in epilepsy. In view of its use in these other CNS
disorders, further studies would be useful to investigate
the use of modafinil for treating cognitive dysfunction
in patients with epilepsy.
5. Replacement of depleted neurotransmitters
Replacement of depleted neurotransmitters may have
some therapeutic potential in epilepsy in the future but,
so far, this approach has not been well explored, as it
has in other specific syndromes, such as Alzheimer’s
disease, with for example the reinforcement of the
cholinergic system [3]. The rationale for this
approach is analogous to dopamine supplementation
in Parkinson’s disease, and cholinergic replacement
for Alzheimer’s disease is based upon underlying neu-
ropathological findings and represents, at the present
time, the main therapy. However, the theoretical basis
of memory disorders in epilepsy is less understood and
the potential neurochemical mechanisms are unknown.
In animal models, seizure-induced memory impair-
ment is reduced by choline supplementation before
or after status epilepticus [22]. Holmes et al. [22]
investigated the effects of pre- and post-natal choline
supplementation in rats with memory deficits associ-
ated with status epilepticus induced with kainic acid.
Two weeks following the kainic acid-induced status,
rats underwent testing of visual-spatial memory using
the Morris water maze test. Rats receiving choline
supplementation performed better in the water maze
than the deficient and control groups. The authors
suggested that choline supplementation can protect rats
from memory deficits induced by status epilepticus.
Clinical studies have reported a useful effect of the
cholinesterase inhibitor donepezil in treating memory
dysfunction in patients with brain injury [53,54], and
one open label study of donepezil in patients with focal
epilepsy suggested improvement in certain aspects of
memory [14]. In this 3-month, open label study of
5–10 mg donepezil in 18 patients, the authors observed
on a battery of neurocognitive tasks, no change in
attention, visual sequencing, mental flexibility or
psychomotor speed, but did report a significantly
greater number of words recalled across learning trials.
Seizure frequency worsened in 2 of the 18 patients but
these changes in seizure frequency were not statistically
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significant. Although seizures, as a potential side effect
of cholinesterase inhibitors, might be of special concern
in patients with epilepsy (and in the patient information
sheet, convulsions are mentioned in overdose), seizures
were never considered a significant adverse event in
pre-marketing trials of donepezil [38]. To our knowl-
edge none of the other cholinergic agonists have been
examined in patients with epilepsy.
6. Putative memory modulators
The administration of putative memory modulators
for neurological disorders has been proposed using
several types of neuropeptides, such as vasopressin,
and of the 20 or more potentially active CNS pep-
tides ACTH, vasopressin and opioid peptides have been
studied the most. Although the results of studies with
experimental models were encouraging, clinical trials
showed evidence of some efficacy on memory, but only
in patients with diabetes insipidus [24] and the benefits
of neuropeptides as memory enhancers has been
seriously questioned [8]. To our knowledge there are
no studies using these molecules in epilepsy.
7. Cerebral blood flow enhancers and nootropics
Several types of drugs are available that claim
to increase cerebral blood flow or to enhance CNS
cellular metabolism. This may be a promising approach
for the treatment of memory disorders in epilepsy,
because some trials with these drugs have shown
protective properties against amnesia in animal models,
such as the electroshock model or that of induced
cerebral hypoxia, that may have some relevance for
human epilepsy [25,36]. Lagergren and Levander [25]
induced artificial hypoxia through a controlled reduc-
tion of heart rate in rats. Piracetam, the first drug to be
developed in this class, had little effect on performance
at normal heart rate, but significantly decreased the
cognitive deterioration caused by the hypoxia when the
heart beat was reduced. The same mechanism may be
assumed for causes other than hypoxia since piracetam
and related nootropics (such as oxiracetam) also have
been shown to protect against other animal models of
amnesia [1].
In epilepsy, this class of drugs may be used as add-
on treatment against the sedative side effects of the
antiepileptic drugs, one of the important causes of
cognitive blunting which may be clinically relevant,
especially if changes in a patient’s antiepileptic drug
regimen are not possible. Some positive results with
oxiracetam have been reported in healthy volunteers
normalizing diazepam-induced memory changes [15]
and with other piractam related molecules in recovery
from the amnestic effects of drug intoxication [3].
A subclass of drugs claimed to enhance cerebral
blood flow are referred to as the nootropic drugs, which
not only act as vigilance-enhancing psychostimulants,
but may also influence specific cognitive targets [16,
17,36]. The mechanism of action of this class of
drugs is assumed to have a selective effect on brain
integrative functions, with no specific or identified
alteration in neuronal excitability or neurotransmitter
activity [16,17]. Several specific cognitive targets for
these drugs have been proposed. Some studies suggest
that cognitive improvement with the nootropic drugs
may be the results of a general psychostimulant effect
on arousal and vigilance [57]. Their quantitative-EEG
profile is very similar to that of general CNS stimu-
lating drugs such as amphetamine, revealing an alpha
rhythm-enhancing effect, an increase in the average
EEG frequency and a decrease in delta activity [15,52,
57].
Interestingly, a specific effect on verbal processing
has been suggested. Piracetam, for example, has been
studied in children with dyslexia. This approach was
based on the observation in early studies, that sub-
stantial improvement of verbal sequential processing
occurred in children with learning disorders after
administration of piracetam [9,39]. In some cases,
improvement of reading disability was found but only in
limited areas and most effects were weak [7,56]. More
pronounced changes were shown in enhanced short
term memory, especially with tests of verbal informa-
tion, as indicated by word recall. Therefore, short-term
memory deficits may be a more promising target for
this class of drug treatment. This is in line with other
clinical studies on piracetam, such as the studies of
Helfgott et al. [18,19] and Levi and Sechi [27] or studies
of related drugs such as etiracetam [37] or
aniracetam [35], all of which imply some effect of this
class of drug on cognition in those with varying degrees
of handicap.
Some authors have evaluated the effect, in patients
with epilepsy, of the nootropic drugs on memory
functions and severe memory impairment. An early
trial involved oxiracetam, a pyrrolidinone derivative,
structurally related to a cyclic form of gamma-amino-
beta-hydroxybutyric acid [51]. For oxiracetam, the
same mode of action is proposed as for piracetam,
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only with more distinctive effects on memory [4],
especially in elderly people with organic brain syn-
dromes [21], in patients with multi-infarct and primary
degenerative dementia [11], and in a heterogeneous
group of dementia patients [29]. A randomized double-
blind placebo-controlled 12 week study of oxiracetam
(800 mg three times daily) vs placebo in people
with epilepsy showed significant improvements in the
neuropsychological profile of the patients, suggesting
enhancement of processing speed as well as of
language comprehension [1]. The authors observed
again the greatest improvement for language. No
specific improvements in memory were found. These
findings are in keeping with reports about piracetam-
induced effects on verbal processing [7,56] and
with studies that found primary effects on alertness and
vigilance [3,57]. However, these results should be
cautiously interpreted because in most of the tests, the
noted improvements were quite weak.
A related compound is levetiracetam, which has now
been successfully introduced for the management of
epilepsy. It mechanism of action as an antiseizure agent
is unknown, and there are few studies on its effects
on cognition. In a single case report, this compound
was shown to improve stuttering [34]. Aldenkamp
and his group have studied the effects on cognition of
levetiracetam in patients with epilepsy, but their single-
blind study of the drug as add on therapy after one week
showed no discernable effect [33].
Another trial involved sabeluzole, a benzothiazol
derivative that also has been shown to be an effective
protector against several types of hypoxia in animal
models. The results in normal volunteers showed
that sabeluzole ameliorated both learning and memory
recall, in conditions of age-related mild hypofunc-
tion [6]. Consolidation of information appeared to
be more efficient and recall of verbal information
from long-term memory was improved even one week
after withdrawal of the drug [6]. Further experiments
consistently have shown most of the positive effects
in subjects with initially relatively poor performance,
such as in a subgroup of patients with the lowest scores
on baseline memory tests [49]. However, the evidence,
taken together, is not clear as to whether sabeluzole
improves memory function per se or reactivates or
restores less specific impaired cognitive function.
Although the mechanism of action of sabeluzole is
not completely clear, its role in improving fast axonal
transport and the effect on voltage-dependent outward
K+ currents may play a role in its cognitive
effects [2].
A randomized, double-blind placebo-controlled par-
allel-group study of 38 patients with epilepsy, assigned
to a 12 week treatment with either sabeluzole or placebo
showed a number of responders (patients with an
improvement that was more than 1 SD on at least three
of the memory tests) in the sabeluzole group (64%),
which was nearly twice the number of responders in the
placebo group (36%) [2]. This suggested a potentially
clinically relevant effect of sabeluzole in the memory
problems associated with epilepsy, and its effect on
long-term verbal memory tests may represent a specific
drug effect.
8. Conclusions
It is now acknowledged that disorders of cognitive
function, especially memory complaints, are frequent
in patients with epilepsy. Although memory problems
are interlinked with the known underlying neurobiol-
ogy of epilepsy in many cases, namely hippocampal
sclerosis, and are likely influenced by ictal and interictal
neurophysiological disturbances of neuronal circuitry
related to memory and attention, it is clear that
antiepileptic drugs can further interfere with cognition,
and some are more potent in this regard than others.
However, in spite of this being such an important
clinical area, little research has been done on the
neuropharmacology of cognitive rehabilitation in
epilepsy, an area in need of urgent study.
Although the evidence is weak, the role of some
drugs in cognitive rehabilitation of patients with
epilepsy seems to be promising. We note in particular
the work with piracetam and its derivatives, and with
sabeluzole, which may provide clues to the trials
of other related chemicals. Two related areas, the
molecular biology of synaptogenesis and the role of
apoptosis represent prominent targets for research in
the field of neuroprotection, and it is known that a
number of psychotropic agents enhance both synapto-
genesis and neurogenesis [50]. Such studies have not
so far yielded comparable data for antiepileptic drugs,
but the role of neuroprotection in preventing long-term
deterioration of function and disability in chronic
disorders, such as epilepsy, is an important area of
future research. Further, a better understanding of
the pathophysiology of cognitive deficits in epilepsy is
the basis for the future development of specific drug
therapies.
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